PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
Financial health
PureTech Health plc financial health
Start with the overall verdict and the rule-based risk checks for PRTC, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.
Cash & Investments
$496.32M
Debt Cushion
$476.56M
Current Ratio
6.6x
Interest Coverage
N/A
Risk checks
3 of 10 flagged
Interest covered
-2.2×
Passes when: Operating income is at least 1.5× interest expense
Debt repayable from cash flow
Negative FCF
Passes when: Free cash flow could repay all debt within 5 years
Stable Altman Z-Score
1.56 → 0.25
Passes when: Z-Score is not falling while below the 2.99 safe zone
Positive equity
Positive
Passes when: Shareholders' equity is above zero
Short-term liquidity
6.6×
Passes when: Current assets are at least 1× current liabilities
Near-term debt covered
56.7×
Passes when: Cash and short-term investments cover debt due within 12 months
Manageable net debt
Net cash
Passes when: Net debt is below 3× EBITDA
Debt growth in line with sales
-25.0% vs 30.6%
Passes when: 3-year debt growth is no more than 5 points above revenue growth
Tangible equity base
0.2%
Passes when: Goodwill and intangibles are below 50% of equity
Limited dilution
-39.3%/yr
Passes when: Diluted share count grows less than 2% a year
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
No financial scores available.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | 1 | 3 | 3 | 4 | 3 | 2 | 3 | 5 | 7 | 5 |
| Altman Z | 1.35 | 0.10 | 1.01 | 2.27 | 3.14 | 1.89 | 3.32 | 1.97 | 1.56 | 0.25 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$254.07M
Q4 2025
Quick Ratio
6.6x
Q4 2025
Current Ratio
6.6x
Q4 2025
Cash Ratio
5.5x
Q4 2025
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q4 2025)
$258.71M
Current assets − current liabilities
Days sales outstanding
637 days
-339 days vs prior year
Days inventory outstanding
0 days
+0 days vs prior year
Days payables outstanding
334 days
-230 days vs prior year
Cash conversion cycle
303 days
-108 days vs prior year
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$19.76M
Q4 2025
Debt/Equity
0.1x
Q4 2025
Debt/Assets
0.0x
Q4 2025
Interest Coverage
—
Q4 2025
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
Net cash $259.14M
Total debt − cash − short-term investments
Net debt / EBITDA
Net cash
Above 3× is elevated
Free cash flow / debt
-431.9%
Share of debt one year of FCF could repay
Years to repay debt
FCF negative
Total debt ÷ free cash flow
Operating cash flow / current liabilities
-1.8×
Above 1× funds a year of obligations
Interest coverage
-2.2×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 56.7×
Balance sheet as of Q4 2025; cash flows FY 2025.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$217.43M
Q4 2025
Assets
$534.71M
Q4 2025
Liabilities
$229.03M
Q4 2025
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q4 2025).
Claims on $534.71M of assets
- Payables0.6%
- Short-term debt0.9%
- Other liabilities41.3%
- Equity57.2%
Goodwill + intangibles
$601K
0.1% of total assets
Share of equity
0.2%
Above 50% leaves little tangible backing
Tangible equity
$311.47M
Equity left after writing off goodwill and intangibles
Deferred revenue
$0
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does PureTech Health plc compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
Alumis Inc. ALMS:NASDAQ | $3.54B | 0.12 | 0.09 | 0.21 | — | 4.34 | 4.34 | 1.22 |
Solid Biosciences Inc. SLDB:NASDAQ | $679.38M | 0.12 | 0.09 | 0.22 | — | 6.14 | 6.14 | 1.79 |
Neurogene Inc. NGNE:NASDAQ | $589.58M | 0.04 | 0.03 | 1.08 | — | 16.56 | 16.56 | 6.33 |
Autolus Therapeutics plc AUTL:NASDAQ | $383.25M | 1.97 | 0.60 | Net cash | — | 5.48 | 5.94 | 1.42 |
Rocket Pharmaceuticals, Inc. RCKT:NASDAQ | $375.63M | 0.09 | 0.08 | 0.25 | — | 6.38 | 6.38 | 2.57 |
Benitec Biopharma Inc. BNTC:NASDAQ | $335.44M | 0.01 | 0.01 | 2.34 | — | 54.67 | 54.67 | 54.24 |
Neumora Therapeutics, Inc. Common Stock NMRA:NASDAQ | $298.31M | 0.00 | 0.00 | 0.78 | — | 5.87 | 5.87 | 5.62 |
Lineage Cell Therapeutics, Inc. LCTX:AMEX | $289.19M | 0.05 | 0.02 | 0.56 | — | 5.20 | 5.20 | 3.59 |
ADC Therapeutics S.A. ADCT:NYSE | $171.71M | -2.36 | 1.36 | Net cash | — | 4.31 | 4.37 | 3.72 |
Quantum-Si incorporated QSI:NASDAQ | $162.69M | 0.02 | 0.02 | 0.18 | — | 7.50 | 7.64 | 0.94 |
Questions
Financial health questions
Common questions about PRTC's balance sheet, answered from the reported figures.
Is PRTC's balance sheet healthy?
PureTech Health plc (PRTC) has a current ratio of 6.59, a quick read on short-term liquidity.
How leveraged is PRTC?
Debt to equity is 0.06, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.